Nasus Pharma Ltd. NSRX
2.55 USD -0.15 (-5.56%)
As ofNov 19, 2026, 3:59 PM EST
2.55 Day range 2.60
1.98 52-week range 9.50
- YTD
- -72.13%
- 1 year
- -63.57%
No chart data for this range yet.
- Market cap
- 29.87M
- EPS (ttm)
- -1.20
- YTD return
- -72.13%
- 1-year return
- -63.57%
- Volume
- 4.67K
- Avg volume
- 16.84K
- Open
- 2.60
- Previous close
- 2.70
- Day's range
- 2.55 – 2.60
- 52-week range
- 1.98 – 9.50
Fundamental scorecard
3 of 25 checks passed on NSRX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
NSRX Revenue — annual 0
NSRX Net income — annual -5.86M
NSRX EPS — annual -0.72
News
Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7
Your note
Sign in to keep a note on NSRX — it syncs with the Stock Master app.
